GSK starts a phase III clinical programme for a potential first-in-class antibiotic, gepotidacin

Source :: Plus Company Updates. October 29, 2019
Publication Year :: 2019
Abstract: Brentford: GlaxoSmithKline Pharmaceuticals Ltd. has issued the following press release: First in a new chemical class of antibiotic with a mechanism of action distinct from any currently approved antibiotic. Investigating [...]

Subjects :: GlaxoSmithKline PLC -- Product development
Sexually transmitted diseases -- Health aspects
Urinary tract infections -- Health aspects
Antibiotics -- Product development -- Health aspects
Medical research -- Health aspects
Pharmaceutical industry -- Product development -- Health aspects
Cystitis
Infection
General interest
News, opinion and commentary

Tools